International Journal of Engineering & Scientific Research
Vol.12 Issue 09, Sep 2024
ISSN: 2347-6532 Impact Factor: 6.660
Journal Homepage: http://www.ijmra.us, Email: editorijmie@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal - Included in the International Serial Directories Indexed & Listed at: Ulrich's Periodicals Directory ©, U.S.A., Open J-Gage as well as in Cabell's Directories of Publishing Opportunities, U.S.A

Strategic Approaches to Environmental Monitoring Programs in Pharmaceutical Manufacturing

Krunal Soni*
Shikha Patel**

Abstract

Environmental monitoring (EM) is pivotal in maintaining contamination control within pharmaceutical manufacturing, particularly in sterile product environments. This review underscores the necessity of designing risk-based EM programs tailored to specific facility needs and processing environments. It outlines critical environmental requirements for sterile product manufacturing, emphasizing the importance of controlling bioburden. Existing regulatory guidelines advocate a risk-based approach to EM, especially in processes that merge elements of both sterile and non-sterile operations. However, a gap exists in specific guidance for hybrid processes, necessitating a framework that identifies critical control points and assesses associated risks. This document provides a technical guide for designing effective EM programs, focusing on sterile manufacturing while also addressing the nuances of low bioburden processes. The principles outlined are adaptable to a range of pharmaceutical operations, aiming to enhance contamination control strategies through robust facility design, reliable documentation, stringent process controls, and continuous improvement initiatives.

Keywords:

Environmental Monitoring (EM);
Bioburden Control;
Sterile ProdictManufacturing;
Contamination Control Strategy (CCS);
Quality Risk Management (QRM).

Author correspondence:

Krunal Soni,
Sr. Director, Quality
eGenesisBio, Cambridge, Massachusetts, USA
Email: krunal.soni@egenesisbio.com; krunalpsoni@gmail.com

1. Introduction

Environmental monitoring (EM) plays a crucial role in assessing the effectiveness of contamination control measures implemented in the manufacturing of pharmaceutical products. These controls are essential for ensuring product quality and safety, especially in environments where sterile product manufacturing is involved. The design and implementation of EM programs must be tailored to the specific needs of each facility and the unique characteristics of its processing environment. This review emphasizes the environmental requirements critical to the manufacture of sterile products and provides key considerations for designing a risk-based EM program. Such a program is particularly vital in supporting the production of low bioburden products, which necessitate processes that maintain a minimal microbial load.

Regulations and guidance documents are widely available to outline EM requirements for sterile, non-sterile, and advanced therapy medicinal products (ATMPs) manufacturing processes. These documents often draw on resources developed for aseptic processes and advocate for a risk-based approach when designing an EM program, particularly for low bioburden processes. This is because many manufacturing operations necessitate stringent contamination control measures that combine elements from both sterile and non-sterile processing guidelines. However, there is no specific guidance that clearly delineates the application of sterile and non-sterile guidelines to such hybrid processes.

*Senior Director, Quality, eGenesis, Cambridge, Masschussetts- USA.
**Senior Manager, Quality Technical Operations, Editas Medicines, Cambridge, Masschussetts- USA.

This document aims to provide a framework for identifying critical control aspects, assessing associated risks, and designing an effective EM program tailored to environments where bioburden control is imperative in the manufacturing process. The principles and strategies outlined in this document can be applied to a wide range of pharmaceutical manufacturing operations, including those involving biologics, small molecules, and other product types. It is important to note that this document serves as technical guidance rather than a set of binding standards, offering best practices for the industry.

1.1 Purpose and Scope

The purpose of this document is to guide the establishment of an environmental monitoring program that is not only robust and meaningful but also practical and innovative. It incorporates the principles of Quality Risk Management (QRM) to ensure the highest standards of contamination control. The document focuses on updated microbiological and airborne particulate control concepts and principles, particularly as they apply to facilities engaged in the manufacture of sterile pharmaceutical products and other designated cleanroom environments.

This document provides a detailed discussion on international standards and regulatory guidance, covering the essential elements of an EM program and its practical applications. A well-structured environmental monitoring program should validate the effectiveness of a comprehensive Contamination Control Strategy (CCS) by emphasizing:

- Sound facility design, including advanced barrier systems such as isolators and Restricted Access Barrier Systems (RABS), as well as proper operation and maintenance practices.
- Established and reliable documentation systems that ensure traceability and compliance.
- Qualified sanitization, disinfection, and decontamination procedures that are critical in maintaining a contamination-free environment.
- Implementation of reliable process controls that maintain the integrity of the manufacturing process.
- Good housekeeping practices that prevent contamination and ensure a clean working environment.
- Effective area access controls to limit the risk of contamination from personnel and materials.
- Consistent sample collection and analysis protocols that ensure accurate monitoring of the environment.
- Effective training programs, certifications, qualifications, and personnel evaluation systems to maintain high standards of performance and knowledge.
- Rigorous quality assurance and control measures for materials, facilities, and equipment.
- Continuous improvement initiatives and quality risk management programs that drive the ongoing enhancement of EM practices.

It is important to note that bulk and intermediate product monitoring, except for pharmaceutical water, are not considered part of standard EM programs and are therefore excluded from the scope of this review.

2. Glossary of Terms

Action Limit
Amicrobial or total airborne particulate limit that, when exceeded, indicates a process is outside of its normal operating range. A response to such an excursion should involve a documented investigation and corrective actions based on the results of that investigation.

Airborne Particulate Count
the total number of particles of a specific size range per unit area of air.

Airborne Viable Particulate Count
The record number of colony forming units or related signal per unit volume of air.

Alert Level
An established value that when exceeded, provides an early warning of potential drift from normal operating conditions and validated state, which does not necessarily give grounds for corrective action but triggers appropriate scrutiny and follow up address the potential problem..

Aseptic Filling
Part of aseptic processing in which a pre stylized or aseptically manufactured product is filled and sealed into sterile containers in a clean room, RABS or isolator.

Aseptic Processing
Handling of product, packaging materials and or processing equipment in a controlled environment in which the air supply, materials, equipment, and personal are controlled to maintain product sterility (2).

Bioburden
viable microorganisms associated with personal, manufacturing environments (air and surfaces), equipment, product packaging, raw materials including water, in-processed materials or finished products.

Cleaning
Chemical or physical means used to remove soil and/or microorganisms from surfaces*(1)*.

Cleanroom
Aroom designed, maintained and controlled to prevent particle and microbiological contamination of a drug product.A clean room is assigned and reproducibly meets an appropriate air cleanliness classification*(1)*.

Clinical Operations Monitoring
Monitoring performed throughout the duration of a process using methods designed to monitor the Environmental Quality of the process and to capture all interventions, transient events and any system deterioration.The design and degree of the monitoring performed should be based on the risk to the process or product being monitored (e.g. closed vs open systems, use of biological safety cabinet, unidirectional flow hood, or other contaminent systems).

Disinfection
The chemical or physical inactivation of a bioburden on inanimate surfaces. Typically, this requires a minimum three-log (3-log) reduction of vegetative microorganisms and a two-log (2-log) reduction of bacterial spores to be achieved in validation*(11).*

Environmental Control Parameters
Conditions and corresponding measurements as associated with facilities and equipment using the control of a manufacturing area that may impact the identity, strength, quality what a priority of a product.Among such parameters are air flow rates and patterns, pressure differentials, materials and personal flow, temperature and relative humidity, as well as non viable and viable particulates*(1)*.

Environmental Monitoring

Dynamic (Opeational) Monitoring
The condition where production operations are actively occurring as defined by the individual firm.Personnel may or may not be present at this time

Routine Monitoring- Frequency based
Monitroing of a facility at a predetermined frequency, as defined by an approved procedure, to provide an overall assessment of the state of control of the facility.

Batch-realted-In-Process or During-Process Monitoring
Monitoring performed during predetermined steps of the production process, as defined by an approved batch record and/our approved procedures or protocols.This can be performed either in the presence or absence of the product.

Continuous
Batch related monitoring, as defined by an approved batch record, to ensure that a state of control is maintained during processing and that any aberrant events are detected.Frequency of monitoring is determined by risk assessment.

Closed System
A process system with equipment designed and operated such that the product is not exposed to the room environment at any point in the process for most biological operations, the system or fluid pathway must remain free of extraneous contamination.

Open System
a process system that exposes the product to the room environment.In this type of system, the room environment is controlled to minimize the risk of extraneous product contamination.

Low Bioburden Product
Product manufactured within a controlled and monitored environment in which the final drug product or process intermediate, as applicable, requires bioburden control, but is not required to be sterile.

Risk Analysis
Estimation of the risk associated with the identified hazards.The following are commonly used tools that can be used to perform risk analysis:
FMEA- Failure Mode Effect Analysis
HACCP- Hazard Analysis And Critical Control Points

Sanitization
Reduction of microbial contaminants do safe levels as judged by public health requirements for the specific country*(1)*.

Sterilization
Validated process used to render product free from viable microorganisms*(1)*.

Toxicity studies
In vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions with the primary goals of identifying:1) an initial safe dose of subsequent dose escalation schemes in humans;2) potential target organs for toxicity and for the study of whether such toxicity is reversible; and 3) safety parameters for clinical monitoring after the appropriate dosing and administering schedule is followed.

3. Comparison betweenLow Bioburden and Traditional Sterile Processes

Sterile drug manufacturing is a highly controlled process designed to ensure that the end product is free of any viable microorganisms, achieved through a combination of sterilizing steps and stringent manufacturing processes and controls. Depending on the physical and chemical properties of the materials involved, as well as specific regulatory requirements, certain bioburden control measures, such as the use of antibiotics, preservatives, solvents, extreme pH levels, sterile filtration, and heat treatments, may not be feasible or appropriate. In many instances, the nature of the process streams used in manufacturing inherently supports microbial proliferation if microorganisms are present. As a result, robust control mechanisms during manufacturing operations are essential to prevent or mitigate microbial growth. Steps such as purification and ultrafiltration, while not explicitly designed to reduce bioburden, can inadvertently contribute to lowering microbial levels when microorganisms are present.

The use of localized unidirectional airflow (UDF) hoods, typically designed to create an EU Grade A/ISO 5 environment, is a common practice in non-sterile manufacturing operations where bioburden control is critical. These hoods are not intended to provide protection for sterile manufacturing activities but rather to minimize microbial contamination during specific open processing steps as part of an overall bioburden control strategy. The level of gowning and other

contamination control measures associated with these hoods should be carefully evaluated and tailored based on the specific operation being performed and the degree of control required.

Once the manufacturing process has been characterized and potential contributors to bioburden have been identified, a comprehensive and well-documented risk assessment should be conducted to pinpoint areas where microbial ingress is most likely to occur. Following the risk assessment, targeted programs can be developed to address the identified risks. While some risks may necessitate ongoing monitoring, others that cannot be completely mitigated should remain under close surveillance to ensure they do not compromise product quality.

In situations where a manufacturing area has been classified according to regulatory or industry standards, the Environmental Monitoring (EM) program is typically expected to comply with the applicable guidelines, even if the area is not used for sterile product manufacturing. However, many of these guidelines are specifically designed for the production of sterile medicinal products and may not fully address the nuances of non-sterile operations where the focus is on controlling rather than eliminating bioburden.

A thorough risk assessment might reveal that only certain aspects of the EU Grade A classification are relevant to the process at hand. Monitoring activities should be aligned with the findings of the risk assessment and focus on the specific monitoring needs of the process. For example, if the primary concern is preventing bioburden introduction during a manufacturing step, the risk assessment may determine that continuous total particulate monitoring during this step provides little value and could even increase the risk to the operation by distracting the operator. In such cases, monitoring for viable organisms may be deemed more critical, while total particulate monitoring may be limited to ensuring the proper function of unidirectional airflow systems.

The UDF hoods, classified as EU Grade A, require aseptic techniques to prevent the introduction of contaminants. The process under these hoods may take less than two minutes to execute, yet air quality regulations necessitate continuous non-viable particulate counts and active airborne viable monitoring throughout the manufacturing process. Annex 1 of the EU GMP guidelines generally expects a sampling size of 1 cubic meter of air, which can take between 5 to 35 minutes to collect, depending on the equipment used. Given the brief duration of the process, fulfilling these sampling requirements can be challenging. However, if the monitoring encompasses the entire process, it would align with the intent of the regulations. A risk assessment should evaluate whether in-process total particulate counts offer meaningful data or if they introduce unnecessary risks. The focus should be on ensuring that the monitoring strategy adequately addresses the most significant risks, such as the introduction of viable organisms, while minimizing potential disruptions to the operation.

Several well-established risk assessment tools, such as flow charts, check sheets, Failure Modes and Effects Analysis (FMEA), and Hazard Analysis and Critical Control Points (HACCP), can be utilized to conduct a thorough risk assessment. To ensure that all aspects of the process are appropriately addressed, the following components should be included:

- Involvement of knowledgeable representatives from relevant functional areas, including validation, manufacturing, quality assurance, facilities, and microbiology.
- Clearly defined risk questions.
- Detailed process maps.
- Facility maps, including personnel and material movement diagrams.
- Production batch records and standard operating procedures (SOPs).

4. Environmental Risk Assessment

Several layers of risk assessments are essential as part of an overall facility risk assessment strategy. These may include a facility (or environmental) risk assessment, a process risk assessment, and an Environmental Monitoring (EM) risk assessment. The environmental risk

assessment should determine the suitability of the facility or environment where the process is conducted. A process risk assessment should identify potential sources of contamination and inherent risks associated with the operational aspects of the process, including points of potential contamination. The EM risk assessment focuses on how contamination risks should be addressed within an effective EM control program. Together, these assessments form the foundation of a comprehensive contamination control strategy for the facility.

This review primarily concentrates on the EM risk assessment, which may be conducted to:

- Develop or enhance programs aimed at identifying, controlling, and monitoring contamination risks, including:
    - Determining the appropriate level of facility control required for the process.
    - Identifying EM locations, sampling frequency, and sampling methodologies.
    - Establishing suitable environmental controls in manufacturing areas based on the type of processing performed.
    - Developing or revising area and material transfer protocols, as well as cleaning and disinfection practices.
- Establish strategies and controls to prevent contamination by personnel.
- Define appropriate flows for personnel, materials, and waste.
- Expand bioburden and endotoxin burden monitoring programs as needed.

EM risk assessments can also be instrumental in investigating contamination events or trends, such as:

- Microbiological contamination in the process train or critical utility systems.
- Adverse data trends in microbial measurement systems.
- Identification and evaluation of potential sources of contamination or atypical microbial recoveries.

4.1 GeneralGuidelines

Risk assessments are crucial for identifying manufacturing process steps or room locations that present the highest potential for introducing contamination into the product, process stream, critical utility system, or environment. A process flow map, informed by production records, relevant SOPs, personnel/equipment/material flow diagrams, and piping and instrumentation diagrams, should be used to delineate individual process steps.

The system owner should outline the process or systems before the multifunctional team develops the risk assessment to ensure the assessment's scope is clearly defined. Facility and operational tours, guided by the process flow map, are recommended to gather information and identify critical factors relevant to the risk assessment

4.2 Criticality Factors

Criticality Criticality factors help in identifying contamination hazards by assessing how each factor could impact the potential for product, process, or environmental contamination. These factors are based on various potential sources of contamination, including:

- Personnel
- Materials/Waste
- Facility Design and Construction
- Facility Cleaning and Disinfection
- Process Design
- Nature of the Product
- Environmental Controls
- Utilities

These factors should be considered applicable to any facility and addressed within the risk assessment.

4.3 Risk Assessment Design

Numerous methodologies are available for designing and implementing a risk assessment. The choice of method should be tailored to the specific process in question and the criticality factors identified. Each risk ranking is conducted according to the selected risk assessment tool. Risk control activities are carried out based on the criteria specified in the relevant risk tool methodology. If a particular location or process step is not well controlled or monitored and is deemed high-risk, it should be flagged as a potential source of microbial ingress, and enhanced contamination control measures should be considered.

4.3.1 Criticality Factors

Criticality factors are criteria that fall into three primary categories: process steps, potential contributors to contamination, and unusual or unexpected sources of contamination. These criteria may be represented as numbers or values to facilitate the evaluation of risk on a scaled basis. The criticality and weighting assigned to each criterion may vary depending on the specific area, process, or other influencing factors.

5. Conclusion

In conclusion, the effective management of environmental monitoring (EM) in pharmaceutical manufacturing, particularly in sterile and low bioburden environments, is indispensable for ensuring product quality and safety. The complexities inherent in these manufacturing processes demand a well-structured EM program that is not only robust but also adaptable to the specific needs of the facility and the nature of the products being manufactured. This review has emphasized the importance of a risk-based approach, which is advocated by current regulatory guidelines. By focusing on identifying critical control points and assessing the associated risks, manufacturers can design EM programs that effectively mitigate contamination risks.

A key takeaway from this review is the necessity of tailoring EM programs to address the unique challenges posed by hybrid processes that combine elements of both sterile and non-sterile manufacturing. The absence of specific guidance for these processes highlights the need for a flexible framework that can be adapted to the specific needs of each operation. The principles outlined in this document, such as the incorporation of Quality Risk Management (QRM) and the emphasis on sound facility design, reliable documentation, and stringent process controls, provide a comprehensive guide for developing effective EM programs.

Furthermore, the importance of continuous improvement in EM practices cannot be overstated. As manufacturing technologies and regulatory expectations evolve, so too must the strategies employed to maintain contamination control. This requires a commitment to ongoing education and training, as well as the adoption of new technologies and methodologies that enhance monitoring capabilities. By fostering a culture of continuous improvement and vigilance, pharmaceutical manufacturers can ensure that their EM programs remain effective and aligned with the latest industry standards.

In summary, this review has provided a detailed exploration of the key considerations for designing and implementing an EM program in pharmaceutical manufacturing. By adhering to the principles outlined here, manufacturers can develop EM programs that not only meet regulatory requirements but also contribute to the overall success of their contamination control strategies. The ultimate goal is to ensure the production of high-quality, safe pharmaceutical products that meet the needs of patients and regulatory authorities alike.

References

[1] Parernteral Drug Association. *Technial Report No. 13 (Revised 2014): Fundamentals of an Environmental Monitroing Program*; PDA: Bethesda, Md., 2014.

[2] International Conference for Harmonization. *Quality Guideline Q10: Pharmaceutical Quality System*; ICH: Geneva, 2008.

[3] European Commission.*Annex 1: Manufacture of Sterile Medicinal Products, EudraLex- Volume 4- Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use*; European Commission: Brussels, 2017.

[4] Krunal S, Shikha P (2024).International Journal of Management, IT & Engineering. *Vol 14, Issue 9*: *Ensuring Quality in Biopharmaceutical Development : A Phase-Appropriate GMP Approach*, IJMRA: Sep 2024; p 14-23.

[5] Shikha P, Krunal S (2024). International Journal of Management, IT & Engineeting. *Vol. 4, Issue 8: Data Integrity: Ensuring Quality and Safety Through Robust Controls and Risk Management*; IJMRA: Aug 2024; p 34-45.

[6] Shikha P, Krunal S (2024). International Journal of Engineeting& Scientific Research. *Vol. 12, Issue 8: Implementing a Lifecycle Approach for Biopharamceutical Process Validation: A Risk Based Strategy*; IJMRA: Aug 2024; p 8-17.

[7] International Conference for Harmonization. *Qulaity Guidance Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients*. 2001.

[8] International Conference for Harmonisation. *Quality Guidance Q12: Technical and Regulatroty Considerations for Pharmaceutical Product Lifecycle Management;* ICH: Geneva, 2017.

[9] European Commission. *Annex 11: Computerised Systems. EudraLex- Volume 4- Good Manufacturing Practice for Medical Products for Human and Veterinary Use*; European Commission: Brussels, 2011.

[10] U.S. Food and Drug Administration. *Guidance for Indusrty: PAT- A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance*; U.S. Department of Health and Human Services: Silver Spring, Md., 2003.

[11] World Health Organization. Annex 6: Good Manufacturing Practices for Sterile Pharmaceutical Products; WHO: Geneva, 2011.

[12] U.S. Food and Drug Administration. Part 133- Drugs; Current Good Manufacturing Practice in Manufacture, Processing, Packing, or Holding. *Fed Regist* **1963**, 28 (120, Part II), 6385-87.

[13] International Society for Pharmaceutical Engineering. *GAMP Guide: Records & Data Integrity*; ISPE: Bethesda, Md., 2017.

[14] European Commission. *Annex 11: Computerised Systems. EudraLex- Volume 4- Good Manufacturing Practice for Medical Products for Human and Veterinary Use*; European Commission: Brussels, 2011.

[15] World Health Organization. *Annex 5: Draft Guidance on Good Data and Record Management Practices*; WHO: Geneva, 2016 p46.

[16] European Agency for the Evaluation of Medicinal Products. *Decision Tree for the Selection of Sterilization Methods: Annex to Note for Guidance on Development Pharmaceutics*; EMA: London, 2000.

[17] U.S. Pharmacopeial Convention. General Chapter <1115> Bioburden Control of Nonsterile Drug Substances and Products. *IN USP 39-NF 34*, USP: Rockville, Md., 2016; p1329.

[18] Parernteral Drug Association. *Technical Report No. 70: Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities*; PDA: Bethesda, Md., 2015.

[19] Parernteral Drug Association. *Technical Report No. 13-2: Fundamentals of an Environmental Monitoring Progam Annex 1: Environmental Monitoring of Facilities Manufcuring Low Bioburden Products;* PDA: Bethesda, Md., 2020.

[20] International Organization for Standardization. *ISO 14644-1: 2025 Cleanrooms and Associated Controlled Environments – Part 1: Classification of air cleanliness by particle concentration*; ISO: Geneva, 2015.